UBS Group’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-37,303
| Closed | -$1.24M | – | 10787 |
|
|
2024
Q3 | $1.24M | Buy |
37,303
+7,162
| +24% | +$247K | ﹤0.01% | 4449 |
|
|
2024
Q2 | $815K | Sell |
30,141
-8,973
| -23% | -$177K | ﹤0.01% | 4603 |
|
|
2024
Q1 | $845K | Buy |
39,114
+23,876
| +157% | +$521K | ﹤0.01% | 4736 |
|
|
2023
Q4 | $91.9K | Buy |
15,238
+6,952
| +84% | +$34.6K | ﹤0.01% | 6214 |
|
|
2023
Q3 | $46.1K | Sell |
8,286
-773
| -9% | -$4.98K | ﹤0.01% | 6336 |
|
|
2023
Q2 | $66.5K | Buy |
9,059
+8,531
| +1,616% | +$64.6K | ﹤0.01% | 6302 |
|
|
2023
Q1 | $2.12K | Sell |
528
-443
| -46% | -$2.16K | ﹤0.01% | 8575 |
|
|
2022
Q4 | $3.17K | Buy |
+971
| New | +$3.9K | ﹤0.01% | 9554 |
|
|
2022
Q3 | – | Sell |
-64
| Closed | – | – | 11846 |
|
|
2022
Q2 | $0 | Buy |
+64
| New | +$294 | ﹤0.01% | 11776 |
|
|
2021
Q4 | – | Sell |
-1,430
| Closed | -$13K | – | 11444 |
|
|
2021
Q3 | $13K | Sell |
1,430
-1,759
| -55% | -$16.2K | ﹤0.01% | 7732 |
|
|
2021
Q2 | $29K | Buy |
3,189
+2,593
| +435% | +$25.8K | ﹤0.01% | 6996 |
|
|
2021
Q1 | $10K | Buy |
+596
| New | +$9.74K | ﹤0.01% | 7982 |
|
UBS Group's LBPH Position: Q4 2024 in Review
UBS Group sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 37,303 shares — an estimated $1.24M sold.
UBS Group first reported a position in LBPH in Q1 2021 and held it in 12 quarters. The position peaked at $1.24M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- UBS Group reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 37,303 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.24M.
- UBS Group first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- UBS Group's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $1.24M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.